Table 4.
Sensitivity analysis: three scenarios (1: excluding dead, 2: cost truncation, 3: intention-to-treat) with difference-in-difference estimators (ATT) and their relative change compared to the baseline scenario
| Excluding dead (1) (n: TM = 630, C = 6607) | Cost truncation (2) (n: TM = 651, C = 7047) | ITT (3) (n: TM = 815, C = 7047) | Baseline | ||||
|---|---|---|---|---|---|---|---|
| ATTa | Δ % | ATTa | Δ % | ATTa | Δ % | ATTa | |
| Total costs | −776.26 | 13.28 | −553.62 | 38.15 | −706.30 | 21.09 | −895.11* |
| Inpatient treatment | −936.43* | 11.33 | −826.14* | 21.77 | −919.54* | 12.93 | −1056.04** |
| Thereof due to COPD | −624.71*** | 2.74 | −597.94** | 6.90 | −554.96** | 13.60 | −642.28*** |
| Outpatient treatment | 63.98 | 7.99 | 68.82* | 1.03 | 65.11* | 6.36 | 69.54* |
| Pharmaceuticals | 101.71 | −10.79 | 130.19 | −41.82 | 145.13 | −58.09 | 91.80 |
| Medical appliances/rehabilitation | −5.51 | −1266 | −0.40 | 0.00 | 2.99 | −642 | −0.40 |
| Indicators for healthcare utilisation | |||||||
| Average length of hospital stay | −1.48*** | −2.91 | n.a. | n.a. | −1.24*** | 13.64 | −1.44*** |
| Thereof due to COPD | −1.72*** | 2.18 | n.a. | n.a. | −1.68*** | 4.673 | −1.76*** |
| Inpatient bed days | −3.01*** | 2.72 | n.a. | n.a. | −2.82*** | 9.05 | −3.10*** |
| Thereof due to COPD | −2.07*** | −0.21 | n.a. | n.a. | −1.86*** | 10.03 | −2.07*** |
| Inpatient stays | −0.21** | 4.12 | n.a. | n.a. | −0.16** | 26.04 | −0.21*** |
| Thereof due to COPD | −0.19*** | −4.95 | n.a. | n.a. | −0.15*** | 14.03 | −0.18*** |
| Thereof ED visits due to COPD | −0.15*** | −3.75 | n.a. | n.a. | −0.13*** | 10.50 | −0.14*** |
| Proportion hospitalised (in %) | −14.95*** | 1.38 | n.a. | n.a. | −11.77*** | 22.36 | −15.16*** |
| Thereof due to COPD | −19.98*** | 1.42 | n.a. | n.a. | −18.86*** | 6.95 | −20.27*** |
| Thereof in ED due to COPD | −16.72*** | 1.64 | n.a. | n.a. | −15.12*** | 11.06 | −17.00*** |
| Physician visits | 1.09*** | 14.82 | n.a. | n.a. | 1.21*** | 5.10 | 1.27*** |
| Thereof due to COPD | 0.77*** | 10.03 | n.a. | n.a. | 0.76*** | 11.85 | 0.86*** |
| Prescriptions | 0.91 | 45.35 | n.a. | n.a. | 1.48** | 11.31 | 1.67** |
| Indicators for mortality | |||||||
| All-cause mortality (in %) | n.a. | n.a. | n.a. | n.a. | −3.73*** | −24.58 | −2.99*** |
Δ %: deviation (in %) of respective sensitivity analysis value from baseline scenario value
* < 0.05; ** < 0.01; *** < 0.0001
aAverage treatment effect for the treated represents excess resource utilisation attributable to DMP